Glaukos Stock 5-Day Winning Spree: Stock Climbs 13%
Glaukos (GKOS) – a developer of therapies for glaucoma and retinal diseases – hit a 5-day winning streak, with cumulative gains over this period amounting to 13%. The company’s market cap has surged by about $777 Mil over the last 5 days and currently stands at $6.7 Bil.
Is this an opportunity or a trap? There is a near-equal mix of good and bad in GKOS stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (For details, see Buy or Sell GKOS).
But here is the interesting part. You are reading about this 13% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Is Group 1 Automotive Stock Optimizing Returns Through the Denominator Effect?
- Tesla Earnings: AI-Fueled CapEx Surge Signals A Structural Business Shift
- What Could Light a Fire Under Advanced Micro Devices Stock
- Can Tesla Stock Withstand These Pressures?
- What Is Happening With Broadcom Stock?
- Does Alphabet Stock Have More Upside?
The following table summarizes the return for GKOS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | GKOS | S&P 500 |
|---|---|---|
| 1D | 3.5% | 0.4% |
| 5D (Current Streak) | 13.1% | 3.8% |
| 1M (21D) | 4.1% | -3.2% |
| 3M (63D) | 5.4% | -3.6% |
| YTD 2026 | 3.3% | -3.4% |
| 2025 | -24.7% | 16.4% |
| 2024 | 88.6% | 23.3% |
| 2023 | 82.0% | 24.2% |
However, big gains can follow sharp reversals – but how has GKOS behaved after prior drops? See GKOS Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 89 S&P constituents with 3 days or more of consecutive gains and 24 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 10 | 20 |
| 4D | 41 | 3 |
| 5D | 35 | 1 |
| 6D | 1 | 0 |
| 7D or more | 2 | 0 |
| Total >=3 D | 89 | 24 |
Key Financials for Glaukos (GKOS)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $383.5 Mil | $507.4 Mil |
| Operating Income | $-108.1 Mil | $-199.6 Mil |
| Net Income | $-146.4 Mil | $-187.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $133.5 Mil | $143.1 Mil |
| Operating Income | $-16.4 Mil | $-139.9 Mil |
| Net Income | $-16.2 Mil | $-133.7 Mil |
While GKOS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.